The genomics technology company will act as majority limited partner for the independently managed Illumina Ventures, providing the cash over a 10-year period.
US-based genome technology provider Illumina yesterday pledged to provide $100m to a newly formed, independently managed venture capital firm called Illumina Ventures over the next 10 years.
Illumina Ventures will invest in early-stage companies developing nucleic acid sequencing technology, and will target those working on technology that will grow the genomics ecosystem or which use genomics for health applications.
Nicholas Naclerio, who has spent almost six years as Illumina’s senior vice-president of corporate and venture development, is the new firm’s…
